

ROGER L. FIDLER
Attorney at Law
12 Marlboro Road
West Milford, NJ 07421
(201) 220-8734
(201) 464-7943 (Fax)
rfidler0099@aol.com

April 7, 2017

OTC Markets Group, Inc.
304 Hudson Street, 3rd Floor
New York, New York 10013-1015

Re: Dolat Ventures, Inc.

Ladies/Gentlemen:

I have been asked by Dolat Ventures, Inc. (the "Issuer") to provide OTC Markets Group, Inc. ("OTC Markets") a letter with respect to the information publicly disclosed by the Issuer and published in the OTC Markets News Service. The prescribed annual digital financial report contained in the annual report disclosure statement was submitted to OTC Markets prior to the submission of this letter as set forth herein below. I understand that this letter will be posted by the Issuer, and will be published, accompanying the Issuer's disclosure, in the OTC Markets News Service. OTC Markets is entitled to rely on such letter in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933.

I am a United States resident and have been retained by the Issuer for the purpose of rendering this letter and related matters. I am serving as regular disclosure counsel for the Issuer, and have been retained also for the purpose of reviewing the current information supplied by the Issuer. I have examined such corporate records and other documents and such questions of law, as I have considered necessary or appropriate for purposes of rendering this letter.

I am licensed to practice law in the States of New York and New Jersey. I am allowed to practice before the Securities and Exchange Commission (the "SEC") and have never been prohibited from practicing before the SEC. As to matters of fact, I have relied on information obtained from public officials, officers of the Issuer and other sources. All such sources are believed to be reliable.

On April 7, 2017, I reviewed the unaudited financial statements provided to OTC Markets by the Issuer in connection with the years ended December 31, 2016 and 2015 and published by OTC Markets on April 7, 2017. These statements were prepared by John Della Donna, CPA, located at 5114 Stoneywood Circle, Mapleton, GA 30126. I have also reviewed documents in connection with the Annual Report and the Officer/Director Disclosure Statement for the period ending December 31, 2016 and posted on April 7, 2017. These documents were posted in connection with the ongoing reporting obligation with the OTC Markets News Service. This letter is submitted in connection with the performance of that obligation.

For the time period ending December 31, 2016, six months thereafter, the information referred to herein constitutes “adequate current public information” concerning the securities and the Issuer and “is available” within the meaning of Rule 144 under the Securities Act of 1933, as amended, (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the securities under Rule 15c2-11 of the Securities Exchange Act of 1934, as amended, (iii) complies as to substance with the OTC Markets Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcm Markets.com, and (iv) has been posted in the OTC Markets News Service.

The Issuer’s transfer agent is VStock Transfer L.L.C., 18 Lafayette, Woodmere, New York 11598 (the “Agent”). The Agent is registered with the Securities and Exchange Commission. The Agent confirmed on March 21, 2017 by email to DeQun Wang, President of the Company, and forwarded to the undersigned the number of issued and outstanding shares of common stock of the Issuer as at December 31, 2016 (699,691,800 shares). I also have (i) personally met with management and a majority of the directors of the Issuer addressed in this Report Period ending December 31, 2017, i.e. Wang DeQun, the Company’s sole officer and director, (ii) reviewed the information published by the Issuer on the OTC Markets News Service and (iii) discussed the information with management and a majority of the directors of the Issuer as at December 31, 2015, i.e. Wang DeQun via a translator. There has been an assertion by Dovid Hauck, a former officer and director, that he owned preferred shares in Dolat Ventures, Inc. constituting control. No shares were ever issued to Mr. Hauck at the time of the transaction with Dr. Stein, the Company’s previous sole officer and director, and indeed no preferred shares of the nature claimed were authorized in the Company’s charter at the time of the transaction with Dr. Stein. Mr. Hauck freely admitted that he has no proof of such an occurrence and demanded \$100,000 in lieu of these shares. Company counsel and the Company are satisfied that the Annual Report addressed herein is a true reflection of events and that control was properly passed to the current control shareholders and should Mr. Hauck seek to continue his assertion the Company will seek declaratory judgement in the courts of Wyoming.

To the best of my knowledge, after inquiry of management and the directors of the Issuer, neither the Issuer of the securities, any 5% holder, or any counsel is currently under investigation by any federal or state regulatory authority for any violation of Federal or state securities laws.

No person other than OTC Markets is entitled to rely on this letter; however, OTC Markets has permission to publish this letter in the OTC Markets News Service for viewing by the public and regulations. As of this date, there have been no promotional activities regarding the securities covered hereby.

Sincerely,

/s/ Roger Fidler
Roger Fidler
Attorney at Law